The twentieth century delivered a 30-year gain in life expectancy. Yet these gains have not translated into a corresponding expansion of healthspan. Critical Mass Ventures funds the science and the scientists working to change that.
The twentieth century witnessed one of the most consequential achievements in human history: a 30-year gain in life expectancy, driven primarily by the conquest of infectious disease through antibiotics, vaccines, and improvements in public health infrastructure. Parallel advances in molecular medicine — the development of insulin therapy, the elucidation of lipid metabolism pathways that enabled statins, and more recently the therapeutic harnessing of GLP-1 receptor biology — transformed once-fatal conditions into manageable ones, extending both survival and quality of life for hundreds of millions of people.
Yet these gains have not translated into a corresponding expansion of healthspan. Globally, the gap between lifespan and healthy life expectancy now stands at 9.6 years, rising to 12.4 years in developed nations and 2.4 years wider for women than for men. Approximately 20% of adult life is now lived with significant morbidity: 85% of adults over 65 carry at least one chronic condition, and 60% carry two or more. Rather than the compression of morbidity toward the end of life that was anticipated as a natural consequence of medical progress, the 21st century is witnessing its expansion.
The biological determinants of this gap remain incompletely understood. Aging itself is not a single process but an ensemble of interacting hallmarks — among them cellular senescence, mitochondrial dysfunction, proteostatic decline, epigenetic dysregulation, and chronic low-grade inflammation — whose relative contributions to disease onset and functional decline vary across tissues, individuals, and populations. Disentangling these mechanisms, identifying the interventions that meaningfully modify them, and navigating the complex translational pathway from experimental model to clinical application represent defining scientific challenges of our time.
Regional and demographic variation in healthspan outcomes suggests that the gap is not fixed — some populations maintain health and functional independence far closer to the end of life than others, implying that biological, behavioral, and structural factors all contribute, and that systematic intervention holds genuine promise.
Critical Mass Ventures is committed to funding the science and the scientists working at this frontier — advancing mechanistic understanding, supporting rigorous translational research, and ensuring that the benefits of emerging healthspan interventions reach the populations that need them most.
A fellowship for late-stage postdoctoral scientists at California institutions. $100,000 award · 3–4 awards · Deadline July 1, 2026.
A fellowship for late-stage postdoctoral scientists at Singapore institutions. S$100,000 award · 1–2 awards · Deadline August 15, 2026.